Form 4: Neurocrine Biosciences Executive Sells Shares
Insider Transaction (Form 4)
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc, sold 10,000 shares of common stock on July 9, 2026 for $179.60 per share.
Summary
- Option exercise/conversion: acquired 10,000 Common Stock at $81.49 ($814,900) on July 9, 2026; holds 64,729 after (Direct).
- Open-market sale: disposed of 10,000 Common Stock at $179.60 ($1,796,014) on July 9, 2026; holds 54,729 after (Direct).
- Option exercise/conversion: disposed of 10,000 Non-Qualified Stock Option on July 9, 2026; holds 4,965 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,796,014 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Darin Lippoldt — Officer (Chief Legal Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Option exercise/conversion | Common Stock | 10,000 | $81 | $814.9K | 64,729 |
| 2026-07-09 | Open-market sale | Common Stock | 10,000 | $180 | $1.8M | 54,729 |
| 2026-07-09 | Option exercise/conversion | Non-Qualified Stock Option | 10,000 | — | — | 4,965 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Option exercise/conversion (10,000 shares) |
| 2026-07-09 | Open-market sale (10,000 shares) |
| 2026-07-09 | Option exercise/conversion (10,000 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, bearish, Darin Lippoldt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.